CAMBRIDGE, Mass., July 27, 2026
CAMP4 Therapeutics announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) and the local Human Research Ethics Committee (HREC) to initiate the first-in-human Phase 1/2 clinical trial of CMP-002, a potential first-in-class disease-modifying therapy for SYNGAP1-related disorder. The milestone marks a significant advancement for the company’s regulatory RNA-targeting platform and represents an important step toward developing a treatment for a rare neurological disorder that currently has no approved disease-modifying therapies. The approval also satisfies a key financing milestone, enabling CAMP4 to raise up to $50 million through the second closing of its previously announced private placement to support the advancement of CMP-002 and its broader pipeline.
Australian Regulatory Clearance Accelerates Clinical Development
The regulatory authorization allows CAMP4 Therapeutics to begin its Phase 1/2 clinical study in Australia, where one of the first patient enrollment sites will be established. Australia was selected as the initial regulatory jurisdiction because of its experienced clinical investigators, established infrastructure for rare disease studies, and the TGA’s streamlined review process for innovative therapies. According to the company, the trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMP-002 in patients with SYNGAP1-related disorder, while additional regulatory submissions are being prepared to expand the study internationally. Company leadership emphasized that the clearance brings a potential disease-modifying intervention closer to patients and families affected by this devastating neurodevelopmental condition.
CMP-002 Targets the Underlying Cause of SYNGAP1 Disorder
CMP-002 is an investigational antisense oligonucleotide (ASO) designed to target a SYNGAP1-specific regulatory RNA (regRNA), increasing SYNGAP1 gene expression and restoring protein levels toward normal. The therapy is administered intrathecally and has demonstrated encouraging preclinical results, including dose-dependent increases in SYNGAP protein expression, reversal of disease-related behavioral abnormalities in animal models, significant improvements in seizure activity, and broad distribution throughout the brain in non-human primates. SYNGAP1-related disorder is caused by mutations that reduce SYNGAP protein production by approximately 50%, leading to intellectual disability, epilepsy, severe behavioral challenges, communication impairment, and other neurological complications. By addressing the underlying genetic deficiency rather than only managing symptoms, CMP-002 aims to provide a transformative treatment approach for patients living with this rare disorder.
Advertisement
Financing Milestone Strengthens Development Strategy
The Australian regulatory clearance also fulfills a critical milestone under CAMP4’s September 2025 Securities Purchase Agreement, making the company eligible to receive up to an additional $50 million in gross proceeds through the second closing of its private financing. The capital is expected to support continued clinical development of CMP-002, expand global trial activities, and advance CAMP4’s broader pipeline of regulatory RNA-targeting therapeutics. Investors participating in the financing include several leading healthcare investment firms alongside CURE SYNGAP1, reflecting continued confidence in the company’s innovative platform. As CAMP4 advances international regulatory activities and prepares to initiate patient enrollment, the company is positioning CMP-002 as a potential first-in-class therapy that could redefine treatment for SYNGAP1-related disorder while validating its broader strategy of restoring healthy protein levels through targeted RNA regulation.
Source: CAMP4 Therapeutics press release
